Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies

Area of Science:

• Cardiovascular Medicine
• Clinical Chemistry
• Genetics

Background:

• Lipoprotein(a) [Lp(a)] is a distinct lipid subfraction characterized by apolipoprotein(a) [apo(a)] attached to apoB100.
• Lp(a) levels are primarily genetic, inversely correlating with apo(a) kringle repeat numbers.
• Epidemiological studies consistently link Lp(a) to cardiovascular disease (CVD) and aortic stenosis.

Purpose of the Study:

• To review the role of Lp(a) in cardiovascular risk.
• To evaluate the impact of current and emerging therapies on Lp(a) levels and CVD outcomes.
• To highlight the potential of novel Lp(a)-targeted therapies.

Main Methods:

• Review of epidemiological studies and clinical trial data.
• Analysis of the effects of various lipid-lowering therapies on Lp(a).
• Discussion of emerging therapeutic strategies targeting Lp(a).

Main Results:

• Standardization of Lp(a) measurement is improving, with consensus favoring its testing in high-risk individuals.
• Conventional lipid-lowering drugs (statins, fibrates, ezetimibe) have minimal impact on Lp(a).
• Niacin and CETP inhibitors reduce Lp(a) but have not definitively reduced CVD events.
• PCSK9 inhibitors lower both cholesterol and Lp(a), with demonstrated CVD event reduction.
• Novel antisense therapies targeting apo(a) offer specific and potent Lp(a) reduction.

Conclusions:

• Lp(a) is a significant, genetically influenced risk factor for cardiovascular disease.
• Current therapies have limited efficacy in reducing Lp(a) and associated CVD risk.
• Emerging Lp(a)-specific therapies, particularly antisense approaches, hold significant promise for CVD risk reduction and require further investigation.